Skip to search formSkip to main content
You are currently offline. Some features of the site may not work correctly.

Ecarin Clotting Time Measurement

Known as: ECT, Ecarin Clotting Time 
The determination of the activity of thrombin inhibitors in a biological specimen based on the generation of meizothrombin.
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Highly Cited
2017
Highly Cited
2017
Background Idarucizumab, a monoclonal antibody fragment, was developed to reverse the anticoagulant effect of dabigatran. Methods… Expand
  • table 1
  • table 1
  • table 2
  • figure 1
  • figure 2
Is this relevant?
Highly Cited
2015
Highly Cited
2015
BACKGROUND Specific reversal agents for non-vitamin K antagonist oral anticoagulants are lacking. Idarucizumab, an antibody… Expand
  • table 1
  • table 2
Is this relevant?
Highly Cited
2015
Highly Cited
2015
BACKGROUND Idarucizumab is a monoclonal antibody fragment that binds dabigatran with high affinity in a 1:1 molar ratio. We… Expand
Is this relevant?
Highly Cited
2013
Highly Cited
2013
Knowledge of anticoagulation status during dabigatran therapy may be desirable in certain clinical situations. 
Is this relevant?
Highly Cited
2011
Highly Cited
2011
Background— Rivaroxaban and dabigatran are new oral anticoagulants that specifically inhibit factor Xa and thrombin, respectively… Expand
  • figure 1
  • figure 2
  • figure 3
Is this relevant?
Highly Cited
2011
Highly Cited
2011
Background and Purpose— Dabigatran-etexilate (DE) recently has been approved for stroke prevention in atrial fibrillation… Expand
  • figure 1
  • figure 2
  • figure 3
  • figure 5
  • figure 4
Is this relevant?
Review
2010
Review
2010
Dabigatran etexilate is an oral, reversible direct thrombin inhibitor that is approved in the EU and several other countries for… Expand
  • table 1
  • figure 1
  • figure 2
  • figure 3
  • figure 4
Is this relevant?
Highly Cited
2010
Highly Cited
2010
AbstractBackground and Objective: Dabigatran etexilate is an oral direct thrombin inhibitor in clinical development for the… Expand
Is this relevant?
Highly Cited
2007
Highly Cited
2007
AIMS The novel direct thrombin inhibitor (DTI), dabigatran etexilate (Boehringer Ingelheim Pharma GmbH & Co. KG), shows potential… Expand
  • table 1
  • figure 1
  • table 2
  • figure 2
  • figure 3
Is this relevant?
Highly Cited
2007
Highly Cited
2007
Dabigatran is a reversible and selective, direct thrombin inhibitor (DTI) undergoing advanced clinical development as its orally… Expand
Is this relevant?